Angionetics Overview

  • Founded
  • 2001
Founded
  • Status
  • Private
  • Latest Deal Type
  • 2ndary - Private
  • Financing Rounds
  • 2

Angionetics General Information

Description

Developer of biotechnology products for cardiac issues. The company is focused on the development and commercialization of novel DNA-based therapeutics designed to promote the heart's innate natural capacity to modulate the formation and growth of cardiac microvascular circulation to enhance blood flow in patients with a variety of ischemia-driven disease conditions and refractory angina and myocardial ischemia due to cardiac microvascular insufficiency (CMI), and other cardiovascular disease conditions.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Corporate Backed or Acquired
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 11750 Sorrento Valley Road
  • Suite 250
  • San Diego, CA 92121
  • United States
+1 (858) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Angionetics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Angionetics‘s full profile, request access.

Request a free trial

Angionetics Executive Team (2)

Name Title Board Seat Contact Info
Christopher Reinhard Chief Executive Officer
Lois Chandler Ph.D Vice President of Product Development
To view Angionetics’s complete executive team members history, request access »

Angionetics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Angionetics‘s full profile, request access.

Request a free trial